Founded to Solve a Real Problem in EV Biomanufacturing.
The EV field has extraordinary potential. What it has lacked is infrastructure. We are building it.
Why Did BioThera Solutions Build an EV Biomanufacturing Platform?
BioThera Solutions was founded to address a critical gap in the extracellular vesicle (EV/exosome) field: the absence of scalable, standardized, and reproducible manufacturing required to bring EV technologies — of all kinds — into real-world application. We set out to build the infrastructure that would make the first truly credible EV skincare company possible, and to lay the foundation for everything that comes after it.
Despite growing scientific evidence for EVs as potent biological delivery systems, the industry has struggled to translate laboratory findings into commercially viable, consistently manufactured products. The problem is not the biology — it is the infrastructure.
We are building that infrastructure — and we started where the need is most immediate. The market for exosome-based skincare has exploded in recent years, driven by genuine scientific interest and surging consumer demand. Dermatologists and aesthetic medicine clinicians increasingly want to offer EV-based treatments to their patients. Yet what they find is a market flooded with products making bold claims, backed by inadequate characterization, inconsistent particle concentrations, and little to no regulatory transparency. There is real demand, and a real absence of products that actually meet clinical standards.
BioThera was built to close that gap. We bring genuine biomanufacturing expertise — MISEV2023-compliant characterization, verified particle concentrations, full regulatory compliance — to a space that has been underserved by rigorous science. Our first product, the mPDEV (Exosome) Serum, is our answer to the question dermatologists have been asking: where is the EV product I can actually trust?
Dermocosmetics is where we earn the right to be taken seriously. The platform we are building today — the plant-derived EV biomanufacturing infrastructure, the clinical evidence base, the regulatory rigour — is the foundation for a broader portfolio of dermocosmetic and EV-based skincare applications that compound on top of it.
Build the scalable plant-derived EV biomanufacturing platform that the EV skincare category has been missing — delivering standardized, characterized, dermatologist-grade extracellular vesicles for dermocosmetic and EV-based skincare applications.
Starting with the mPDEV (Exosome) Serum as our commercial validation point, we are establishing the manufacturing infrastructure, characterization rigour, and clinical evidence base that credible EV skincare requires.
To define what credible, science-led EV skincare looks like — and to build the biomanufacturing backbone that the dermocosmetic and EV-based skincare category needs to mature.
We are in the early chapters of the EV skincare era. Our ambition is to set the standard for the category — building the manufacturing foundation, characterization rigour, and clinical evidence base that consumers, clinicians, and regulators can trust.
What Principles Guide BioThera Solutions?
Radical Scientific Transparency
We make no claims we cannot substantiate. Every product specification, characterization result, and regulatory status is communicated with precision. Vague language and marketing hyperbole have no place in how we operate.
Uncompromising Excellence
Manufacturing standards, characterization protocols, formulation quality — we apply the same rigor at every stage, regardless of where we are in the development cycle. Quality is built in, not inspected in.
Innovation
The EV space is early. The manufacturing infrastructure needed to make EVs clinically and commercially viable does not yet fully exist — we are building it. That requires genuine scientific creativity and technical courage.
Execution
Ideas in biotech are plentiful. Rigorous, reliable execution is rare. We close the gap between scientific potential and real-world deployment — consistently, on schedule, and to spec.
Ottawa, Ontario, Canada
BioThera Solutions is headquartered in Ottawa, Ontario. Our location provides proximity to regulatory bodies, a growing life sciences ecosystem, and the clinical and research collaborators central to our work.
Company Clarification
BioThera Solutions (Canada) is an independent biotechnology firm specializing exclusively in plant-derived extracellular vesicles (EVs). We have no affiliation with Bio-Thera Solutions, Ltd. (China), which focuses on biosimilars and antibody-drug conjugates (ADCs). Our mission is to build the biomanufacturing infrastructure that EV-based skincare requires — beginning with our flagship plant-derived EV serum and scaling into a broader portfolio of dermocosmetic and EV-based skincare applications.
BioThera Solutions works exclusively with selected partners.
We selectively engage with dermatology clinics, aesthetic medicine practices, and research collaborators where there is strong scientific and strategic alignment. We are not broadly in market at this time.
Partnership inquiries are reviewed individually.
Inquire About PartnershipESG and Responsibility
BioThera Solutions operates with environmental, social, and governance (ESG) principles built into how we work. Our nano vesicles are derived from medicinal plants rather than animal or human tissue, and our biomanufacturing process is designed to be scalable and resource-efficient. We are transparent about our science and communicate clearly with clinical partners, suppliers, and the broader research community. Our governance practices are aligned with Health Canada cosmetic notification requirements, and our scientific reporting follows MISEV (Minimal Information for Studies of Extracellular Vesicles) guidelines. Sustainability and ethical conduct are part of how we build for the long term.